AbSorber AB

Stockholm, Sweden

AbSorber AB

Stockholm, Sweden
SEARCH FILTERS
Time filter
Source Type

News Article | November 2, 2016
Site: www.newsmaker.com.au

Wiseguy Reports  Medical Devices sector report, “Hematology Diagnostic Tests - Medical Devices Pipeline Assessment, 2015" provides an overview of Hematology Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Diagnostic Tests pipeline products. This report is prepared using data sourced from in-house databases, secondary and primary research by Wiseguy Reports team of industry experts. - Extensive coverage of the Hematology Diagnostic Tests under development  - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities  - The report reviews the major players involved in the development of Hematology Diagnostic Tests and list all their pipeline projects  - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage  - The report provides key clinical trial data of ongoing trials specific to pipeline products  - Recent developments in the segment / industry The report enables you to -  - Formulate significant competitor information, analysis, and insights to improve R&D strategies  - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage  - Identify and understand important and diverse types of Hematology Diagnostic Tests under development  - Develop market-entry and market expansion strategies  - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline  - In-depth analysis of the product’s current stage of development, territory and estimated launch date Table of Contents  1 Table of Contents 2      1.1 List of Tables 6      1.2 List of Figures 18  2 Introduction 19      2.1 Hematology Diagnostic Tests Overview 19  3 Products under Development 22      3.1 Hematology Diagnostic Tests - Pipeline Products by Stage of Development 22      3.2 Hematology Diagnostic Tests - Pipeline Products by Segment 23      3.3 Hematology Diagnostic Tests - Pipeline Products by Territory 25      3.4 Hematology Diagnostic Tests - Pipeline Products by Regulatory Path 26      3.5 Hematology Diagnostic Tests - Pipeline Products by Estimated Approval Date 27  4 Hematology Diagnostic Tests - Pipeline Products under Development by Companies 28      4.1 Hematology Diagnostic Tests Companies - Pipeline Products by Stage of Development 28      4.2 Hematology Diagnostic Tests - Pipeline Products by Stage of Development 32  5 Hematology Diagnostic Tests Companies and Product Overview 40      5.1 Abbott Diagnostics Company Overview 40        5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 40      5.2 AbSorber AB Company Overview 42        5.2.1 AbSorber AB Pipeline Products & Ongoing Clinical Trials Overview 42      5.3 Alere Inc. Company Overview 43        5.3.1 Alere Inc. Pipeline Products & Ongoing Clinical Trials Overview 43      5.4 Analyticon Biotechnologies AG Company Overview 45        5.4.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 45      5.5 Apollo Medical Devices LLC Company Overview 57        5.5.1 Apollo Medical Devices LLC Pipeline Products & Ongoing Clinical Trials Overview 57      5.6 Asta Fluidic Technologies, Inc. Company Overview 58        5.6.1 Asta Fluidic Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 58      5.7 Auer Precision Company Overview 59        5.7.1 Auer Precision Pipeline Products & Ongoing Clinical Trials Overview 59      5.8 Axxin Company Overview 60        5.8.1 Axxin Pipeline Products & Ongoing Clinical Trials Overview 60      5.9 Beckman Coulter, Inc. Company Overview 61        5.9.1 Beckman Coulter, Inc. Pipeline Products & Ongoing Clinical Trials Overview 61      5.10 Besst Test Company Overview 62        5.10.1 Besst Test Pipeline Products & Ongoing Clinical Trials Overview 62 Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.


Lindberg L.,AbSorber AB | Liu J.,AbSorber AB | Gaunitz S.,Karolinska University Hospital | Nilsson A.,Recopharma AB | And 3 more authors.
Glycobiology | Year: 2013

Assays for quantification, and methods for removal, of anti-A and anti-B antibodies are the key for the success of ABO incompatible organ transplantation programs. In order to produce tools that can be used as substrates in tests for anti-A/anti-B quantification and specificity determination or as affinity matrices in extracorporeal immunoadsorption (IA) columns, we engineered Chinese hamster ovary (CHO) cells secreting mucin-type fusion proteins carrying blood group A or B determinants on defined O-glycan core saccharide chains. Besides the P-selectin glycoprotein ligand-1/mouse immunoglobulin G2b (PSGL-1/mIgG2b) cDNA, CHO cells were transfected with plasmids encoding core 2 (β1,6GlcNAc-T1) or core 3 (β1,3GlcNAc-T6 and β1,3Gal-T5) enzymes together with α1,2Fuc-T1 or α1,2Fuc-T2 and the A or B gene-encoded α1,3GalNAcT or α1,3Gal-T, respectively. Selected clones with the correct glycophenotype were expanded and cultured in shaker flasks and Wave bioreactors. Western blotting was used to characterize purified fusion protein and liquid chromatography-mass spectrometry was used to characterize the released O-glycans. Clones producing PSGL-1/mIgG2b carrying O-glycans with A and B determinants on type 1 (Galβ3GlcNAc), type 2 (Galβ4GlcNAc) and type 3 (Galβ3GalNAcα) outer core saccharide chains were established. The conversion of CHO cells from exclusive inner core 1 (Galβ3GalNAc) to core 3 (GlcNAcβ3GalNAc) O-glycan producers was almost complete, whereas conversion to inner core 2 (GlcNAcβ6GalNAc) O-glycans was incomplete as was the α2-fucosylation of the core 1 chain. Sialylation may prevent these biosynthetic steps. The clinical utility of the blood group A and B substituted mucin-type fusion proteins as substrates in enzyme-linked immunosorbent assay or as affinity matrices in IA columns is explored. © 2012 The Author.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.4-1 | Award Amount: 3.74M | Year: 2012

The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they dont have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aims of this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.


Deenick E.K.,Ontario Cancer Institute | Deenick E.K.,University of Toronto | Deenick E.K.,Garvan Institute of Medical Research | Elford A.R.,Ontario Cancer Institute | And 11 more authors.
European Journal of Immunology | Year: 2010

Regulatory T (Treg) cells are crucial for maintaining peripheral tolerance and controlling T-cell responses. The generation of Treg in the thymus requires TCR triggering and CD28 costimulation. Engagement of these receptors induces a number of signalling pathways, including the activation of NF-κB via PKCθ and the Bcl-10/CARMA1/MALT complex. Previous studies have shown that PKCθ, Bcl-10 and CARMA1 are important for Treg development. It is unclear, however, whether different members of the NF-κB family contribute to Treg development or homeostasis. In this study, we show that Treg numbers are reduced in the absence of c-Rel but not NF-κB1 (p50). Furthermore, using mixed bone marrow chimeras from WT and KO animals, we demonstrate that the requirement for PKCθ, Bcl-10 and c-Rel is T-cell intrinsic, and cannot be rescued by the presence of WT cells. Therefore, c-Rel and NF-κB1 have differential roles in Treg development. © 2010 Wiley-VCH Verlag GmbH & Co. KGaA.


Alheim M.,Karolinska University Hospital | Johansson S.M.,Karolinska University Hospital | Hauzenberger D.,Karolinska University Hospital | Grufman P.,AbSorber AB | Holgersson J.,Karolinska University Hospital
Tissue Antigens | Year: 2010

Complement-dependent cytotoxicity or flow cytometric lymphocyte crossmatch (LXM) tests may fail to detect clinically significant antibodies (Abs) against non-human leukocyte antigen (HLA). A flow cytometric endothelial precursor cell crossmatch (EPCXM) test (XM-ONE ®) is available for detection of Abs against donor endothelial precursor cells (EPCs). We showed that lymphocytes co-purified with EPCs can be used in LXM tests allowing simultaneous detection of Abs reactive with donor EPCs and lymphocytes. The lymphocyte population co-purified with EPCs on anti-Tie-2 Ab-coupled magnetic beads contained CD 8 + and CD 4 + T-cells, B-cells, and natural killer (NK)- and natural killer T (NKT)-cells. HLA class I antigen expression was slightly higher on CD 3 + lymphocytes co-purified on Tie-2 Ab beads than on unseparated lymphocytes, whereas HLA class I and II antigen levels on CD 19 + lymphocytes were not significantly different. Sera from 10 patients with panel-reactive Abs were tested on cells from nine donors using flow cytometric LXM and EPCXM tests. There was a very good correlation (R 2 = 0.94) between the channel shift values obtained on unseparated and Tie-2 Ab bead-isolated T-lymphocytes, whereas the correlation between the channel shift values obtained on the two B-lymphocyte populations was lower (R 2 = 0.71). T- and B-lymphocytes co-purified with EPCs can be used in LXM tests enabling simultaneous detection of donor lymphocyte- and EPC-reactive Abs in a single-tube XM-ONE ® assay. © 2010 John Wiley & Sons A/S.


Lindberg L.,AbSorber AB | Liu J.,AbSorber AB | Holgersson J.,AbSorber AB
Methods in Molecular Biology | Year: 2013

Metabolic engineering of mammalian cells for optimized glycosylation is usually done to improve activity and the pharmacokinetic features of glycoprotein therapeutics. The field is mainly focused around engineering of N-glycans. We have created a platform in which recombinant mucin-type immunoglobulin fusion proteins are used as scaffolds for multivalent expression of O-glycans with diagnostic or therapeutic potential. The methods used to make stable CHO cell lines secreting a mucin-type fusion protein with blood group A or B determinants following expression of up to five different cDNAs are described. © Springer Science+Business Media New York 2013.


Lindberg L.,AbSorber AB | Johansson S.M.,AbSorber AB | Liu J.,AbSorber AB | Grufman P.,AbSorber AB | Holgersson J.,AbSorber AB
Transfusion | Year: 2011

BACKGROUND: Hemagglutination for detection and semiquantification of ABO antibodies is associated with large center-to-center variations and poor reproducibility. Because acceptance for transplantation and diagnosis of rejection in ABO-incompatible transplantation rely on the levels and specificity of ABO antibodies, reproducible tests that allow their detection and specificity determination are required. STUDY DESIGN AND METHODS: The level of chain type-specific anti-A and anti-B were analyzed in the sera of 44 healthy individuals of known ABO blood group using an enzyme-linked immunosorbent assay (ELISA) with polyacrylamide (PAA) conjugates of blood group A and B trisaccharides or Type 2 chain A and B tetrasaccharides. Selected sera were further analyzed by hemagglutination and in an ELISA with Types 1 to 4 chain A or B neoglycolipids (NGL) as antigens. RESULTS: Immunoglobulin (Ig)G anti-A and anti-B levels were higher (p ≤ 0.05) in blood group O than in B and A individuals. More IgM anti-A and anti-B cross-reactivity was detected in AB serum on PAA-conjugated A and B trisaccharides than on the tetrasaccharides. One of 11 blood group B and two of 12 A individuals had IgG antibodies binding the tetrasaccharide despite lack of, or very low reactivity with, the trisaccharides. IgG antibodies preferring the A and B Type 2 tetrasaccharides were of the IgG2 subclass. The NGL ELISA further supported the presence of chain type-specific anti-A and -B antibodies among nonsensitized, healthy individuals. CONCLUSION: An ELISA with structurally defined ABH antigens will allow the antibody class and fine specificity of ABO antibodies to be determined, which may improve risk assessment in ABO-incompatible transplantation.


The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.


The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.


The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection and blood typing.

Loading AbSorber AB collaborators
Loading AbSorber AB collaborators